T. Rowe Price lists 10.1% of Bicara Therapeutics (NASDAQ: BCAX) in 13G/A

Rhea-AI Filing Summary

BICARA THERAPEUTICS INC ownership update: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,605,780 shares of common stock, representing 10.1% of the class as disclosed in an amended Schedule 13G/A. The filing states T. Rowe Price "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner," denying beneficial ownership. The report lists 6,597,481 shares as sole voting power and 6,605,780 shares as sole dispositive power. The filing is signed by Ellen York, Vice President, dated 04/08/2026.

Insights

Institutional Ownership Analyst

T. Rowe Price reports a 10.1% position while disclaiming beneficial ownership.

The amendment lists 6,605,780 shares and a 10.1% stake as the reported position. The filing records sole voting and dispositive power in nearly identical counts, indicating control over voting and disposition for the reported shares.

Because the filing includes an explicit denial of beneficial ownership, the practical effect depends on underlying client or fiduciary relationships; subsequent filings or disclosures may clarify economic interest.

Key Figures

Shares beneficially owned: 6,605,780 shares Percent of class: 10.1% Sole voting power: 6,597,481 shares

3 metrics

Shares beneficially owned 6,605,780 shares Amount reported on Schedule 13G/A

Percent of class 10.1% Percent of common stock reported in Item 4(a)-(b)

Sole voting power 6,597,481 shares Number with sole power to vote listed in Item 4(c)(i)

Key Terms

Schedule 13G/A, Beneficial ownership, Sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 1 and form type lines"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership financial

"Amount beneficially owned: 6605780 (Item 4)"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 6605780"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

BICARA THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

055477103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 055477103

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,597,481.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,605,780.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,605,780.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.1 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BICARA THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 245 MAIN STREET, CAMBRIDGE, MA, 02142
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6605780
(b)	Percent of class: 10.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6597481
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6605780
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	04/08/2026

FAQ

What does the Schedule 13G/A from T. Rowe Price (BCAX) report?

It reports ownership of 6,605,780 shares, equal to 10.1% of common stock. The amendment lists voting and dispositive powers and includes a written denial of beneficial ownership by T. Rowe Price.

Does T. Rowe Price claim it beneficially owns BCAX shares?

No. The filing includes an explicit statement denying beneficial ownership. It still lists voting and dispositive power counts of 6,597,481 and 6,605,780, respectively, in the amendment.

How much voting power does T. Rowe Price report for BCAX?

The amendment reports 6,597,481 shares as sole voting power. Shared voting power is listed as 0, per the Schedule 13G/A fields in the filing.

When was the Schedule 13G/A signed and by whom?

The amendment was signed by Ellen York, Vice President on 04/08/2026. The cover records the reporting entity as T. Rowe Price Investment Management, Inc.